Studies on GPR17: G Protein-coupled Receptor Involved in Pain Perception and Neurotransmission
Studies on GPR17: G Protein-coupled Receptor Involved in Pain Perception and Neurotransmission
GPR17 (UDP/CysLT receptor) is a G protein-coupled receptor that is expressed in various tissues and plays an important role in many physiological processes. It is a member of the GPR family, which includes over 100 different genes that encode for G protein -coupled receptors. GPR17 is one of the most well-studied GPR genes, and a significant amount of research has been conducted on its biology and potential as a drug target.
GPR17 is a transmembrane receptor that is located at the end of the cell's cytoplasm. It consists of an extracellular domain, a transmembrane region, and an intracellular domain. The transmembrane region of GPR17 contains the extracellular portion of the receptor and is involved in its interaction with ligands. The intracellular domain is responsible for the internal signaling processes that occur after the receptor is activated.
GPR17 is involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. It is expressed in various tissues, including the brain, eye, ears, skin, and reproductive organs. It is also involved in many different signaling pathways, including the regulation of pain, inflammation, and stress.
One of the most significant functions of GPR17 is its role in pain perception. GPR17 is known to play a key role in the regulation of pain sensitivity, and it is involved in the development of neuropathic pain. Studies have shown that activation of GPR17 can cause the release of endogenous opioids, such as endorphins and delta-opioids, which can alleviate pain. Additionally, GPR17 has been shown to play a role in the modulation of pain modalities, such as thermal and electrical pain sensitivity.
GPR17 is also involved in neurotransmission. It is known to play a role in the regulation of neurotransmitter release from axons, and it is involved in the transmission of signals from the nervous system to other tissues. Studies have shown that GPR17 is involved in the regulation of neurotransmitter release in response to various stimuli, including sensory inputs and neurotransmitters.
GPR17 is also involved in hormone signaling. It is known to play a role in the regulation of hormone signaling, including the regulation of insulin secretion from pancreatic beta cells. Studies have shown that GPR17 is involved in the regulation of insulin secretion in response to changes in blood glucose levels, and that it can serve as a potential drug target for the treatment of diabetes.
In addition to its involvement in pain perception, neurotransmission, and hormone signaling, GPR17 is also involved in other physiological processes. It is known to play a role in the regulation of cell adhesion, and it is involved in the formation of tight junctions in epithelial cells. Additionally, GPR17 is involved in the regulation of ion channels in various tissues, including muscle and cardiac cells.
GPR17 is also a potential drug target. Studies have shown that GPR17 is involved in the regulation of a wide range of physiological processes, and that it is potential for the development of drugs that target its activity. For example, GPR17 has been shown to play a role in the regulation of pain sensitivity, and it is potential for the development of drugs that can alleviate pain. Additionally, GPR17 is involved in the regulation of neurotransmission, and it is potential for the development of drugs that can modulate neurotransmitter release.
In conclusion, GPR17 is a well-studied G protein-coupled receptor that is involved in a wide range of physiological processes. It is expressed in various tissues
Protein Name: G Protein-coupled Receptor 17
Functions: Dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes (CysLTs). Signals through G(i) and inhibition of adenylyl cyclase. May mediate brain damage by nucleotides and CysLTs following ischemia
The "GPR17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR17 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND | GRB10 | GRB14 | GRB2
